摘要 |
The present invention relates to an azole compound represented by the formula [I] wherein W is S or O; R is -COOR<SUP>7</SUP>, -X<SUP>1</SUP>-A<SUP>1</SUP>-COOR<SUP>7 </SUP>(R<SUP>7 </SUP>is H, alkyl) or tetrazolyl; R<SUP>1</SUP>, R<SUP>2</SUP>, R<SUP>3 </SUP>and R<SUP>4 </SUP>are H and the like; A is -(CH<SUB>2</SUB>)<SUB>m</SUB>-X- (X is -N(R<SUP>8</SUP>)-, -C(R<SUP>9</SUP>)(R<SUP>10</SUP>)-, -CO- or -CO-N(R<SUP>8</SUP>)-); B is aryl or aromatic heterocyclic group; R<SUP>5 </SUP>is H and the like; R<SUP>6 </SUP>is -(Y)<SUB>s1</SUB>-(A<SUP>2</SUP>)<SUB>s</SUB>-Z (Y is -O-, -S(O)<SUB>t</SUB>-, -N(R<SUP>13</SUP>)-, -N(R<SUP>14</SUP>)-CO-, -N(R<SUP>14</SUP>)-SO<SUB>2</SUB>-, -SO<SUB>2</SUB>-N(R<SUP>14</SUP>)- and the like, A<SUP>2 </SUP>is alkylene, and Z is cycloalkyl, aryl, aromatic heterocyclic group, indanyl, piperazinyl, a prodrug thereof or a pharmaceutically acceptable salt thereof. The compound [I] of the present invention has a protein tyrosine phosphatase 1B inhibitory activity, and is useful as a therapeutic agent for diabetes, a therapeutic drug for diabetic complications or a therapeutic drug for hyperlipidemia.
|